Evidence map›Paper›PMID 39698518›Full record

ArticleHealth science reports2024

Prevalence of Plasmid-Mediated Quinolone Resistance Genes in

Samira Alipour, Mina Owrang, Mohsen Rajabnia, Meysam Olfatifar, Hossein Kazemian, Hamidreza Houri

Abstract read
In one paragraph

Article in Health science reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Samira AlipourFoodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases Shahid Beheshti University of Medical Sciences Tehran Iran.
Mina OwrangFaculty of Medical Science, Sari Branch Islamic Azad University Sari Iran.
Mohsen RajabniaNon-Communicable Diseases Research Center Alborz University of Medical Sciences Karaj Iran.
Meysam OlfatifarGastroenterology and Hepatology Diseases Research Center Qom University of Medical Sciences Qom Iran.
Hossein KazemianClinical Microbiology Research Center Ilam University of Medical Sciences Ilam Iran.ORCID 0000-0003-4590-396X
Hamidreza HouriFoodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases Shahid Beheshti University of Medical Sciences Tehran Iran.ORCID 0000-0002-6813-0229

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: Emerging evidence suggests that ciprofloxacin and other quinolones can be effectively used as adjuncts to immunosuppressive therapy in managing inflammatory bowel disease (IBD). Clinical isolates of Enterobacterales frequently exhibit quinolone resistance. Additionally, increased IBD severity has been linked to the proliferation of Enterobacterales in the gut. This study aimed to explore the frequency of fluoroquinolone resistance and the presence of associated resistance genes in Methods: In this research, we conducted a study that involved the isolation and examination of Results: From the colonic and ileal biopsies of 121 patients with IBD, we isolated 107 unique strains of Conclusion: Our results reveal that a significant number of patients with IBD carry quinolone-resistant

Indexed as

ciprofloxacinEscherichia coliinflammatory bowel diseaseplasmid‐mediated quinolone resistance

Identifiers

PMID39698518
PMCPMC11652390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.